Autotransplantation for mantle cell lymphoma

Area of Science:

• Hematology
• Oncology

Background:

• Mantle cell lymphoma (MCL) accounts for 5-9% of non-Hodgkin lymphomas.
• MCL often presents with lymphadenopathy and extranodal involvement, leading to a median survival of 3-5 years with standard immunochemotherapy.

Purpose of the Study:

• To evaluate the role of autologous stem cell transplantation (ASCT) in improving survival for MCL patients.
• To compare ASCT outcomes in first remission versus relapse settings.

Main Methods:

• Review of clinical data and trial results for MCL patients undergoing ASCT.
• Analysis of progression-free survival (PFS) rates based on remission status at the time of ASCT.

Main Results:

• ASCT in relapsed MCL shows disappointing PFS of 20-40%.
• ASCT in first complete remission significantly improves PFS to 60-80% at 5 years.
• Patient age over 60 limits ASCT applicability.

Conclusions:

• ASCT is recommended for eligible MCL patients during first remission to improve long-term outcomes.
• Further research is needed to reduce relapse rates post-transplantation and expand ASCT eligibility.